Details for Patent: 10,112,903

Which drugs does patent 10,112,903 protect, and when does it expire?

Patent 10,112,903 protects ARISTADA and ARISTADA INITIO KIT and is included in two NDAs.

This patent has forty-seven patent family members in twenty-two countries.

Summary for Patent: 10,112,903

Title:	Heterocyclic compounds for the treatment of neurological and psychological disorders
Abstract:	Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.
Inventor(s):	Julius F. Remenar, Laura Cook Blumberg, Tarek A. Zeidan
Assignee:	Morgan Stanley Senior Funding Inc
Application Number:	US15/875,478
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,112,903
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,112,903

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-001	Oct 5, 2015		RX	Yes	No	10,112,903			Y		TREATMENT OF SCHIZOPHRENIA
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No	10,112,903			Y		TREATMENT OF SCHIZOPHRENIA
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	10,112,903			Y		TREATMENT OF SCHIZOPHRENIA
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No	10,112,903			Y		TREATMENT OF SCHIZOPHRENIA

International Family Members for US Patent 10,112,903

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	077239
Argentina	109699
Australia	2010266018
Australia	2010266040